Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CTSO NYSE:MLSS NASDAQ:NMTC NASDAQ:SINT On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCTSOCytosorbents$0.46-5.9%$0.56$0.44▼$1.39$28.82M1.35163,128 shs77,811 shsMLSSMilestone Scientific$0.42-4.3%$0.34$0.22▼$0.92$36.73M1.041.33 million shs137,669 shsNMTCNeuroOne Medical Technologies$3.44-1.1%$4.29$3.27▼$6.96$29.65M0.5134,629 shs20,858 shsSINTSintx Technologies$2.03-9.4%$2.42$1.86▼$6.78$8.77M0.6665,521 shs116,533 shs5G Stocks: The Path Forward is ProfitableClick the link to see MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCTSOCytosorbents-5.94%-6.50%-19.47%-42.48%-54.10%MLSSMilestone Scientific-4.31%+7.31%+2.95%+47.85%-54.34%NMTCNeuroOne Medical Technologies-1.15%-3.10%-20.00%-31.75%-4.78%SINTSintx Technologies-9.38%-9.38%-15.42%-25.37%-27.76%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCTSOCytosorbents$0.46-5.9%$0.56$0.44▼$1.39$28.82M1.35163,128 shs77,811 shsMLSSMilestone Scientific$0.42-4.3%$0.34$0.22▼$0.92$36.73M1.041.33 million shs137,669 shsNMTCNeuroOne Medical Technologies$3.44-1.1%$4.29$3.27▼$6.96$29.65M0.5134,629 shs20,858 shsSINTSintx Technologies$2.03-9.4%$2.42$1.86▼$6.78$8.77M0.6665,521 shs116,533 shs5G Stocks: The Path Forward is ProfitableClick the link to see MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCTSOCytosorbents-5.94%-6.50%-19.47%-42.48%-54.10%MLSSMilestone Scientific-4.31%+7.31%+2.95%+47.85%-54.34%NMTCNeuroOne Medical Technologies-1.15%-3.10%-20.00%-31.75%-4.78%SINTSintx Technologies-9.38%-9.38%-15.42%-25.37%-27.76%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCTSOCytosorbents 2.00Hold$5.381,071.02% UpsideMLSSMilestone Scientific 3.00Buy$1.00140.79% UpsideNMTCNeuroOne Medical Technologies 2.40Hold$11.67239.15% UpsideSINTSintx Technologies 2.50Moderate Buy$9.33359.77% UpsideCurrent Analyst Ratings BreakdownLatest SINT, MLSS, NMTC, and CTSO Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/4/2026SINTSintx Technologies Maxim GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$6.005/20/2026SINTSintx Technologies HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$10.005/13/2026NMTCNeuroOne Medical Technologies LADENBURG THALM/SH SHSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$1.60 ➝ $8.005/11/2026NMTCNeuroOne Medical Technologies Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)4/21/2026SINTSintx Technologies Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)4/13/2026SINTSintx Technologies HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$10.004/8/2026CTSOCytosorbents Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)4/8/2026SINTSintx Technologies Ascendiant Capital MarketsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$16.00 ➝ $12.003/26/2026CTSOCytosorbents D. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$10.003/13/2026NMTCNeuroOne Medical Technologies Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold(Data available from 6/6/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCTSOCytosorbents$37.06M0.78N/AN/A$0.09 per share5.10MLSSMilestone Scientific$8.90M4.13N/AN/A$0.11 per share3.78NMTCNeuroOne Medical Technologies$12.10M2.45N/AN/A$0.85 per share4.05SINTSintx Technologies$1.02M8.60N/AN/A$0.80 per share2.54Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCTSOCytosorbents-$8.20M-$0.19N/A15.30N/A-31.85%-235.57%-37.88%8/6/2026 (Estimated)MLSSMilestone Scientific-$6.93M-$0.05N/AN/AN/A-52.01%-60.26%-40.23%N/ANMTCNeuroOne Medical Technologies-$3.61M-$0.85N/AN/AN/A-68.35%-98.33%-69.85%8/13/2026 (Estimated)SINTSintx Technologies-$10.36M-$5.07N/AN/AN/A-1,058.60%-366.49%-115.04%8/13/2026 (Estimated)Latest SINT, MLSS, NMTC, and CTSO EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/15/2026Q1 2026SINTSintx Technologies-$0.66-$0.70-$0.04-$0.70$0.30 million$0.38 million5/13/2026Q1 2026CTSOCytosorbents-$0.06-$0.08-$0.02-$0.08$9.40 million$8.86 million5/12/2026Q2 2026NMTCNeuroOne Medical Technologies-$0.2267-$0.25-$0.0233-$0.25$2.58 million$2.39 million3/25/2026Q4 2025CTSOCytosorbents-$0.05-$0.09-$0.04-$0.09$9.22 millionN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthCTSOCytosorbentsN/AN/AN/AN/AN/AMLSSMilestone ScientificN/AN/AN/AN/AN/ANMTCNeuroOne Medical TechnologiesN/AN/AN/AN/AN/ASINTSintx TechnologiesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCTSOCytosorbents4.701.090.81MLSSMilestone ScientificN/A2.851.86NMTCNeuroOne Medical TechnologiesN/A4.383.28SINTSintx TechnologiesN/A1.040.70Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCTSOCytosorbents32.87%MLSSMilestone Scientific5.79%NMTCNeuroOne Medical Technologies16.07%SINTSintx Technologies18.38%Insider OwnershipCompanyInsider OwnershipCTSOCytosorbents7.30%MLSSMilestone Scientific12.51%NMTCNeuroOne Medical Technologies11.80%SINTSintx Technologies4.08%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCTSOCytosorbents22062.79 million58.21 millionOptionableMLSSMilestone Scientific3088.45 million58.61 millionOptionableNMTCNeuroOne Medical Technologies208.62 million7.60 millionOptionableSINTSintx Technologies404.32 million4.14 millionNot OptionableSINT, MLSS, NMTC, and CTSO HeadlinesRecent News About These CompaniesSINTX Technologies Announces Raise of Approximately $5.0 Million of Capital, Including a $4.5 Million Private Placement Priced At-the-Market Under Nasdaq RulesJune 3 at 9:00 AM | globenewswire.comLD Micro: SINTX Technologies to Present at the LD Micro Invitational XVI ConferenceMay 18, 2026 | finanznachrichten.deSINTX Technologies to Present at the LD Micro Invitational XVI ConferenceMay 17, 2026 | newsfilecorp.comNSintx Technologies (SINT) price target decreased by 25.00% to 12.24April 15, 2026 | msn.comHC Wainwright & Co. initiates coverage of Sintx Technologies (SINT) with buy recommendationApril 13, 2026 | msn.comSINTX Technologies Provides Corporate Business Update Highlighting First Human Implant, Strategic Transformation, and Commercial ExecutionMarch 23, 2026 | globenewswire.comSINTX Technologies Announces First-In-Human Surgery Using FDA-Cleared SINAPTIC® Foot & Ankle ImplantMarch 19, 2026 | globenewswire.comSintx Technologies (NASDAQ:SINT) Director Purchases $21,848.60 in StockMarch 11, 2026 | insidertrades.comSINTX Technologies names Ryan Elmore President to drive commercial expansion of SiN biomaterialsMarch 2, 2026 | voxelmatters.comVSINTX Technologies Appoints Ryan Elmore President to Lead Channel Expansion of Silicon Nitride Biomaterial PlatformsFebruary 18, 2026 | globenewswire.comSINTX Technologies to Participate in Noble Capital Markets’ Emerging Growth Virtual Equity Conference on February 4–5January 29, 2026 | markets.businessinsider.comSINTX Technologies to Participate in Noble Capital Markets' Emerging Growth Virtual Equity Conference on February 4–5January 29, 2026 | globenewswire.comSintx Technologies (SINT) price target decreased by 36.00% to 16.32December 21, 2025 | msn.comInsider Buying: Sintx Technologies (NASDAQ:SINT) CIO Buys 8,200 Shares of StockDecember 10, 2025 | insidertrades.comSintx Technologies (NASDAQ:SINT) CIO Gregg Honigblum Acquires 65,000 SharesDecember 9, 2025 | insidertrades.comAscendiant Capital maintains Sintx Technologies (SINT) buy recommendationDecember 8, 2025 | msn.comSINTX Technologies to Participate in Sidoti & Company Investor ConferenceDecember 8, 2025 | markets.businessinsider.comSINTX Technologies Signs Supply Agreement with EVONIK to Manufacture Silicon Nitride–PEEK Compound for AI-Assisted, 3D-Printed Patient-Specific ImplantsDecember 1, 2025 | globenewswire.comSINTX Reports Pivotal Third Quarter Business Update and Financial Highlights Driven by FDA Clearance, Product and IP Portfolio Expansions and Increased Operational EfficienciesNovember 13, 2025 | markets.businessinsider.comInsider Buying: Sintx Technologies (NASDAQ:SINT) CIO Acquires 10,000 Shares of StockNovember 11, 2025 | insidertrades.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeSINT, MLSS, NMTC, and CTSO Company DescriptionsCytosorbents NASDAQ:CTSO$0.46 -0.03 (-5.94%) Closing price 06/5/2026 04:00 PM EasternExtended Trading$0.46 0.00 (0.00%) As of 06/5/2026 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology in the United States, Germany, and internationally. Its flagship product is CytoSorb, an extracorporeal cytokine adsorber for adjunctive therapy in the treatment of sepsis, adjunctive therapy in other critical care applications, prevention, and treatment of perioperative complications, and maintaining or enhancing the quality of solid organs harvested from donors for organ transplant; and offers VetResQ, a device for adjunctive therapy in the treatment of sepsis, pancreatitis, and other critical illnesses in animals. The company also develops CytoSorb-XL, a device for adjunctive therapy in the treatment of sepsis and other critical illnesses; HemoDefend blood purification technology platform to reduce contaminants in the blood supply that can cause transfusion reactions or disease when administering blood and blood products to patients, and removal of anti-A and anti-B blood group antibodies from whole blood and plasma; K+ontrol for treatment of severe hyperkalemia in patients with life-threatening conditions; and ContrastSorb for the removal of IV contrast in blood administered during CT imaging, an angiogram, or during a vascular interventional radiology procedure to reduce the risk of contrast-induced nephropathy. In addition, it develops BetaSorb, a device for the prevention and treatment of health complications caused by the accumulation of metabolic toxins in patients with chronic renal failure; DrugSorb, a device to remove drugs and chemicals from the blood; and DrugSorb-ATR, an antithrombotic removal system. The company was formerly known as MedaSorb Technologies Corporation and changed its name to Cytosorbents Corporation in May 2010. Cytosorbents Corporation was founded in 1997 and is headquartered in Princeton, New Jersey.Milestone Scientific NYSE:MLSS$0.42 -0.02 (-4.31%) Closing price 06/5/2026 04:00 PM EasternExtended Trading$0.42 +0.00 (+0.17%) As of 06/5/2026 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Milestone Scientific Inc., a biomedical technology research and development company, patents, designs, develops, and commercializes diagnostic and therapeutic injection technologies, and devices for medical, dental, and cosmetic use in the United States, China, and internationally. The company operates through Dental and Medical segments. Its products include CompuDent and STA Single Tooth Anesthesia System that are used for all dental procedures that require local anesthetic. In addition, the company offers CompuFlo, a computer-controlled drug delivery system for the painless delivery of drugs, anesthetics, and other medicaments, as well as for the aspiration of bodily fluids or previously injected substances, and disposable injection handpiece for the tactile control during the injection. Further, it provides CompuFlo Epidural, a computer-controlled anesthesia system for use in various medical applications. Additionally, the company offers company offers CompuMed for use in various medical procedures performed in plastic, hair restoration, and colorectal surgery, as well as podiatry, dermatology, orthopedics, and various other disciplines. Milestone Scientific Inc. was incorporated in 1989 and is headquartered in Roseland, New Jersey.NeuroOne Medical Technologies NASDAQ:NMTC$3.44 -0.04 (-1.15%) Closing price 06/5/2026 04:00 PM EasternExtended Trading$3.52 +0.08 (+2.44%) As of 06/5/2026 05:24 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.NeuroOne Medical Technologies Corporation, a developmental stage company, provides solutions for EEG recording, brain stimulation and ablation solutions for patients suffering from epilepsy, Parkinson's disease, dystonia, essential tremors, and chronic pain due to failed back surgeries and other related neurological disorders. It also fucuses on applications for other areas, such as depression, mood disorders, pain, incontinence, high blood pressure, and artificial intelligence. It has a strategic partnership with RBC Medical Innovations to develop a radio frequency ablation generator. The company was incorporated in 2009 and is based in Eden Prairie, Minnesota.Sintx Technologies NASDAQ:SINT$2.03 -0.21 (-9.38%) Closing price 06/5/2026 04:00 PM EasternExtended Trading$2.02 -0.01 (-0.49%) As of 06/5/2026 05:42 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Sintx Technologies, Inc., an advanced ceramics company, engages in the research, development, and commercialization of medical devices manufactured with silicon nitride for biomedical, technical, and antipathogenic applications in the United States. It provides solid and porous silicon nitride; silicon nitrite powder; and silicon nitride coating products, as well as silicon nitride composite materials, polyetheretherketone, and polyetherketoneketone. The company was formerly known as Amedica Corporation. Sintx Technologies, Inc. was incorporated in 1996 and is headquartered in Salt Lake City, Utah. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 06/01 - 06/05 Samsara Just Answered The AI Question—Is Wall Street Ready To Listen? A Lulu of a Miss Sends Lululemon to New Lows—Look Out Below Five Below Down 12% Post Earnings—Is the Selloff Overdone? IREN's 800MW Bet Flips the AI Power Switch Buy the Dip? Broadcom's AI Moat Is Wider Than Ever CrowdStrike Earnings Beat Sparks Selloff—Buy the Dip? The Market Has Ollie’s Bargain Outlet Completely Wrong Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
